CK Life Sciences (HKG:0775) expects an attributable loss of HK$126.6 million in 2024, compared with a profit of HK$17.3 million a year prior, a Thursday filing with the Hong Kong bourse said.
The biotechnology company attributed the forecast mainly to a rise in R&D investments and a decline in the fair value of its vineyard portfolio.
Shares of the company were up nearly 2% in recent trade.